Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trichostatin A · 2 trials · 2 indications
Subjects will be asked about AEs weekly during the evaluation phase and at every follow-up visit; descriptions of AEs will include, at a minimum: date of onset, date ended, severity, seriousness, relationship to the study drug, and outcome.
Measured by spontaneous reporting of adverse events (AEs)
| Arm | Type | Description |
|---|---|---|
| Trichostatin A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Trichostatin A | DRUG | Topical Study Drug |
Inclusion Criteria: * Willingness to provide signed and dated written voluntary informed consent. * Adults with diagnosis of mild-to-severe DLSO/DSO affecting at least one great toenail. * Positive microscopic examination with KOH for dermatophyte hyphae. * Positive dermatophyte culture or mixed de...
Trichostatin A is an investigational small molecule being studied for the treatment of onychomycosis of the toenail and relapsed or refractory hematologic malignancies. It is currently in clinical development for these conditions.
Trichostatin A is being developed by Vanda Pharmaceuticals Inc., a company traded on the NASDAQ under the ticker symbol VNDA.
Trichostatin A is in Phase 2 clinical development for onychomycosis of the toenail. It is also being studied in a Phase 1 trial for relapsed or refractory hematologic malignancies. The drug is investigational and has not been approved by regulatory authorities.
Trichostatin A is being evaluated in two clinical trials. NCT07065773 is a Phase 2 study in patients with mild to severe onychomycosis, enrolling 50 participants in the United States. NCT03838926 is a Phase 1 tolerability study in subjects with relapsed or refractory hematologic malignancies, enrolling 42 participants in the United States and Poland.
Trichostatin A is a distinct investigational compound. No alternative names for this drug have been disclosed in the clinical trial records.